GIP analogues have been developed as potential treatments for type 2 diabetes, and ameliorate impaired insulin release from the pancreas and facilitate the normalisation of insulin signaling and hyperglycaemia [32,33]. The gene discussed is INS; the disease is Hyperglycemia.